Early, Middle, or Late Administration of Zoledronate Alleviates Spontaneous Nociceptive Behavior and Restores Functional Outcomes in a Mouse Model of CFA‐Induced Arthritis

Simple item page
AudienciaPúblico en generales_ES
CoberturaMéxicoes_ES
Fecha de ingreso2026-09-15T00:30:25Z
Fecha de publicación2014-01-01
ResumenAbstract Preclinical Research This study was performed to evaluate whether early, middle, or late treatment of zoledronate, an approved bisphosphonate that blocks bone resorption, can reduce nociceptive behaviors in a mouse arthritis model. Arthritis was produced by repeated intra‐articular knee injections of complete Freund's adjuvant (CFA). A dose‐response curve with zoledronate (3, 30, 100, and 300 μg/kg, i.p., day 4 to day 25, twice weekly for 3 weeks) was performed, and the most effective dose of zoledronate (100 μg/kg, i.p.) was initially administered at different times of disease progression: day 4 (early), day 15 (middle), or day 21 (late) and continued until day 25 after the first CFA injection. Flinching of the injected extremity (spontaneous nociceptive behavior), vertical rearings and horizontal activity (functional outcomes), and knee edema were assessed. Zoledronate improved both functional outcomes and reduced flinching behavior. At day 25, the effect of zoledronate on flinching behavior and vertical rearings was greater in magnitude when it was given early or middle rather than late in the treatment regimen. Chronic zoledronate did not reduce knee edema in CFA‐injected mice nor functional outcomes in naïve mice by itself. These results suggest that zoledronate may have a positive effect on arthritis‐induced nociception and functional disabilities.es_ES
Doihttps://doi.org/10.1002/ddr.21183es_ES
URIhttps://riuat.uat.edu.mx/handle/123456789/2369
Idiomaeses_ES
EditorialWileyes_ES
RelaciónDrug Development Researches_ES
URL relacionadohttps://doi.org/10.1002/ddr.21183es_ES
DerechosAcceso abierto (Metadatos de producción científica)es_ES
Licenciahttp://purl.org/coar/access_right/c_abf2es_ES
FuenteDrug Development Research
TítuloEarly, Middle, or Late Administration of Zoledronate Alleviates Spontaneous Nociceptive Behavior and Restores Functional Outcomes in a Mouse Model of CFA‐Induced Arthritises_ES
TipoArtículoes_ES
ArbitradoHa sido Arbitradoes_ES
AutorMorado‐Urbina, Carlos Eduardo
AutorAlvarado‐Vázquez, Perla Abigail
AutorMontiel‐Ruiz, Rosa Mariana
AutorAcosta‐González, Rosa Issel
AutorCastañeda‐Corral, Gabriela
AutorJiménez‐Andrade, Juan Miguel
AutorMorado‐Urbina, Carlos Eduardoes_ES
AutorAlvarado‐Vázquez, Perla Abigailes_ES
AutorMontiel‐Ruiz, Rosa Marianaes_ES
AutorAcosta‐González, Rosa Isseles_ES
AutorCastañeda‐Corral, Gabrielaes_ES
AutorJiménez‐Andrade, Juan Migueles_ES
InstituciónUniversidad Autónoma de Tamaulipas
InstituciónUniversidad Autónoma de Tamaulipases_ES
Número7es_ES
Rango de páginas438-448es_ES
URL relacionadahttps://doi.org/10.1002/ddr.21183
Tipo de artículoIndexado
Tipo de artículoIndexadoes_ES
Volumen75es_ES

Files

Collections

Documentación Cientifica